ZEVRA THERAPEUTICS, INC. ZVRA

Latest FY: 2025 Healthcare Biotechnology
Market Price $12.05
Market Cap $712.34M
P/E Ratio 8.93
Quick Peer Compare (Healthcare):
Revenue (FY 2025) ↑350.9% YoY
$106.47M
3-Yr CAGR: 116.7%
Net Income ↑178.9% YoY
$83.23M
Net Margin: 78.2%
Free Cash Flow ↑96.5% YoY
-$2.43M
FCF Yield: -0.34%
EPS (Diluted) ↑159.2% YoY
$1.35
Basic: $1.40
Return on Equity Efficiency
53.8%
ROA: 29.2%

📊 Multi-Year Historical Performance & Trends

Financial Performance History Revenue, Net Income & Free Cash Flow
Margins Trend (%) Gross, Operating & Net Margins
Balance Sheet Strength Cash, Debt & Equity
Cash Flow Generation Operating Cash Flow vs CapEx vs FCF

📈 Year-over-Year (YoY) Growth History (ZVRA)

All monetary values in millions ($M)
Fiscal Year Revenue Revenue YoY Gross Profit Net Income Net Inc YoY Diluted EPS EPS YoY Div / Sh Div Yield Op. Cash Flow Free Cash Flow FCF YoY
FY 2016 $-16.5M $-1.13 0.00% $-29.8M $-30.4M
FY 2017 $-43.4M -162.7% $-2.96 -161.9% 0.00% $-33.1M $-33.3M -9.4%
FY 2018 $-56.5M -30.1% $-3.15 -6.4% 0.00% $-54.2M $-54.2M -62.9%
FY 2019 $12.8M $2.8M $-24.5M +56.6% $-0.83 +73.7% 0.00% $-23.7M $-23.8M +56.2%
FY 2020 $13.3M +3.5% $2.3M $-12.8M +48.0% $-3.21 -286.7% 0.00% $-1.9M $-2.0M +91.7%
FY 2021 $28.6M +115.6% $16.4M $-8.6M +33.0% $-2.11 +34.3% 0.00% $10.4M $10.3M +624.2%
FY 2022 $10.5M -63.5% $10.1M $-41.5M -385.6% 0.00% $-18.7M $-18.8M -282.0%
FY 2023 $27.5M +162.6% $24.5M $-46.0M -10.8% 0.00% $-33.5M $-33.8M -79.9%
FY 2024 $23.6M -14.0% $16.2M $-105.5M -129.1% $-2.28 0.00% $-69.7M $-69.7M -105.9%
FY 2025 $106.5M +350.9% $90.0M $83.2M +178.9% $1.35 +159.2% 0.00% $-1.6M $-2.4M +96.5%
$

Valuation

Market Price $12.05
Market Cap $712.34M
Enterprise Value $711.86M
P/E Ratio 8.93
P/B Ratio 4.61
FCF Yield -0.34%
Dividend Yield N/A
Shares Outstanding 59,115,100
%

Profitability & Margins

Gross Margin 84.52%
Operating Margin 59.12%
Net Margin 78.17%
Return on Equity (ROE) 53.82%
Return on Assets (ROA) 29.23%
Asset Turnover 0.37x
Revenue 3-Yr CAGR 116.73%
🛡️

Financial Health & Liquidity

Current Ratio 5.68
Cash Ratio 1.59
Debt / Equity 0.400
Debt / Assets 0.217
Cash & Equivalents $62.41M
Total Debt $61.93M
Book Value / Share $2.62
💧

Cash Flow Efficiency

Operating Cash Flow -$1.60M
Capital Expenditures (CapEx) $835.00K
Free Cash Flow -$2.43M
OCF / Revenue -1.50%
FCF / Revenue -2.29%
FCF 3-Yr CAGR N/A
🏷️

Per Share Metrics

EPS (Diluted) $1.35
EPS (Basic) $1.40
Dividends / Share N/A
Book Value / Share $2.62
EPS YoY Growth 159.21%
🏛️

Balance Sheet (FY 2025)

Total Assets $284.73M
Total Liabilities $130.07M
Stockholders' Equity $154.66M
Current Assets $223.01M
Current Liabilities $39.28M